CEO Dr James Garner speaks about Kazia’s recent milestones with proactive investors

Our Chief Executive Officer, Dr James Garner, was interviewed this morning by Proactive Investors on the company’s recent milestones and outlook.

In the interview, Dr Garner discusses:

  • Kazia’s recent presentation of new data from the ongoing phase I study of Cantrixil in ovarian cancer at the European Society for Medical Oncology in Barcelona, Spain.
  • The company’s recent presentation on its ongoing phase II study of GDC-0084 in glioblastoma at the annual meeting of the European Association of Neuro-Oncology in Lyon, France.
  • Kazia’s win of an inaugural ANZLF Trans-Tasman Innovation & Growth Award.
  • The recent milestone achieved in Kazia’s study with US-based St Jude’s Children’s Research Hospital in the childhood brain cancer, DIPG.
  • The implications of the World Health Organisation selecting a provisional name for Kazia’s lead drug, GDC-0084.
  • The upcoming milestones and value catalysts for the company.

Watch the video interview here.


For more information on Kazia register your interest below.

Register Interest